A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin

Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy

Mitchell K. Higashi · JAMA · 2002 · 1.1K citations

Medicine, Genetics, Pharmacology +17

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

Owen A. O’Connor, Steven M. Horwitz, Tamás Masszi et al. · Journal of Clinical Oncology · 2015 · 547 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

Jane A. Plumb, Paul W. Finn, Robert J. Williams et al. · PubMed · 2003 · 313 citations

Medicine, Oncology, Pharmacology +15

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements

Christina L. Aquilante, Taimour Langaee, Lucy E. Correa-López et al. · Clinical Pharmacology & Therapeutics · 2006 · 270 citations

Medicine, Genetics, Pharmacology +14

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

Giuseppe Giaccone, Arun Rajan, Arlene Berman et al. · Journal of Clinical Oncology · 2011 · 188 citations · Full text

Medicine, Oncology, Pharmacology +12